A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)

European Journal of Cancer

Volumn 47, Issue 15, 2011, Pages 2331-2340

  Gaafar, Rabab M ^a   Surmont, Veerle F ^b   Scagliotti, Giorgio V ^c   Van Klaveren, Rob J ^d   Papamichael, Demetris ^e   Welch, John J ^f   Hasan, Baktiar ^f   Torri, Valter ^g   Van Meerbeeck, Jan P ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF TURIN   (Italy)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e Bank of Cyprus Group Oncology Centre   (Cyprus)

^f EORTC DATA CENTER   (Belgium)

^g MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Chemotherapy; EGFR; EORTC; Gefitinib; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN DERIVATIVE; ERLOTINIB; GEFITINIB;

ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; EARLY TERMINATION OF CLINICAL TRIALS; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 80053365381     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.06.045     Document Type: Article

References (25)

1. Cancer.net [Internet]. Virginia: American Society of Clinical Oncology (ASCO), Inc., c2005-10 [cited 2010 Oct]. Available from: www.cancer.net.
2. J. Ferlay, P. Autier, and M. Boniol Estimates of the cancer incidence, mortalityin Europe in 2006 Ann Oncol 18 2007 581
3. NSCLC Meta-analyses Collaborative Group Chemotherapy in addition to supportive care improves survival in advanced non-small cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomised controlled trials J Clin Oncol 26 28 2008 4617 4625
4. F.A. Shepherd, J. Dancey, and R. Ramlau Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103 (Pubitemid 30324363)
5. N. Hanna, F.A. Shepherd, and F.V. Fosella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 9 2004 1589 1597 (Pubitemid 41079796)
6. S. Caponi, E. Vasile, and L. Ginocchi Second-line treatment for non-small-cell lung cancer: one size does not fit all Clin Lung Cancer 11 2010 320 327
7. P.M. Fidias, S.R. Dakhil, and A.P. Lyss Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer J Clin Oncol 27 2009 591 598
8. T. Ciuleanu, T. Brodowicz, and C. Zielinski Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised double-blind phase 3 study Lancet 374 2009 1432 1440
9. F. Ciardiello, and G. Tortora EGFR antagonists in cancer treatment N Engl J Med 358 2008 1160 1174
10. G. Giaccone, R.S. Herbst, and C. Manegold Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1 J Clin Oncol 22 2004 777 784 (Pubitemid 41103588)
11. R.S. Herbst, G. Giaccone, and J.H. Schiller Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2 J Clin Oncol 22 2004 785 794 (Pubitemid 41103589)
12. U. Gatzemeier, A. Pluzanska, and A. Szczesna Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 2007 1545 1552 (Pubitemid 46733081)
13. R.S. Herbst, D. Prager, and R. Hermann TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 2005 5892 5899
14. K. Takeda, T. Hida, and T. Sato Randomised phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203) J Clin Oncol 28 5 2010 753 760
15. T.S. Mok, Y.L. Wu, and L.A. Zhang Small step towards personalized medicine for non- small cell lung cancer Discovery Med 8 43 2009 227 231
16. F.A. Shepherd, and J. Rodrigues Pereira Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132 (Pubitemid 41058344)
17. F. Grossi, M. Aita, and A. Follador Sequential, alternating or maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature Oncologist 12 4 2007 1541 1564
18. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumours J Natl Cancer Inst 92 2000 205 216 (Pubitemid 30099779)
19. K. Kelly, K. Chansky, and L.E. Gaspar Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023 J Clin Oncol 26 15 2009 2450 2456
20. N. Thatcher, A. Chang, and P. Parikh Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 9496 2005 1527 1537 (Pubitemid 41540110)
21. F. Cappuzzo, T. Ciuleanu, and L. Stelmakh Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 6 2010 521 529
22. Soon YY, Stockler MR, Askie LA, BoyerMJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 2009; doi: 10.1200/JCO.2008.19.4522.
23. E.S. Kim, T. Mok, and V. Hirsh Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial The Lancet 372 2008 1809 1812
24. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
25. C. Zhou, Y.L. Wu, and G. Chen Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin plus gemcitabine in Chinese advanced non-small cell lung cancer patients with EGFR activating mutations Ann Oncol s21 2010 viii6